A Method of Treating a Tumor in a Patient Based on an Immune Gene Expression Signature
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2018/067319, filed Dec 21, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,412,639 | Method of Characterizing a Tumor Based on an Immune Gene Expression Signature in Regulatory T Cell (TREG)-Enriched Tumor Samples In force · High confidence UsedRemaining | Nantomics, LLC | In force | High confidence | ||
| US 11,756,651 | A Method of Treating a Tumor in a Patient Based on an Immune Gene Expression Signature In force · High confidence | Nantomics, LLC | In force | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.